HT-ALZ Showed Improvement on Several Tests of
Cognitive Function
HT-ALZ Showed Positive Benefits with
Reductions in Anxiety
Completed Dose Response Study Leads
Hoth to Begin Formulation Development
NEW
YORK, Aug. 9, 2023 /PRNewswire/ -- Hoth
Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused
biopharmaceutical company, today announced that HT-ALZ, a
therapeutic in development for the treatment of Alzheimer's
Disease ("AD"), achieved positive preclinical end points in a
study conducted at Washington
University, St. Louis.
Subjects treated with HT-ALZ show improvement on several tests
of cognitive function, including spatial learning and memory,
sensorimotor gating, and contextual associative memory.
HT-ALZ showed positive benefits with reducing anxiety- like
behavior in mice.
AD is a neurodegenerative disease that is characterized by
aggregates of amyloid β (Aβ) plaques and neurofibrillary tangles of
Tau protein in the brain, which contribute to the clinical symptoms
of the disease, such as dementia. Previously Hoth reported study
results focused on investigating the effect of orally
administered HT-ALZ to reduce the concentration of Aβ in the brain
interstitial fluid, using an established Alzheimer's Disease mouse
model (aged APP/PS1+/- mice). The initial data from those studies
showed a significant decrease in Aβ in both male and female
APP/PS1+/- mice after acute treatment with HT-ALZ, compared to
placebo-treated animals and baseline Aβ levels.
About Hoth Therapeutics, Inc.
Hoth Therapeutics
is a clinical-stage biopharmaceutical company dedicated to develop
innovative, impactful, and ground-breaking treatments with a goal
to improve patient quality of life. We are a catalyst in
early-stage pharmaceutical research and development, elevating
drugs from the bench to pre-clinical and clinical testing.
Utilizing a patient-centric approach, we collaborate and partner
with a team of scientists, clinicians, and key opinion leaders to
seek out and investigate therapeutics that hold immense potential
to create breakthroughs and diversify treatment options. To learn
more, please visit https://ir.hoththerapeutics.com/ .
Forward-Looking Statement
This press release
includes forward-looking statements based upon Hoth's current
expectations which may constitute forward-looking statements for
the purposes of the safe harbor provisions under the Private
Securities Litigation Reform Act of 1995 and other federal
securities laws, and are subject to substantial risks,
uncertainties and assumptions. These statements concern Hoth's
business strategies; the timing of regulatory submissions; the
ability to obtain and maintain regulatory approval of existing
product candidates and any other product candidates we may develop,
and the labeling under any approval we may obtain; the timing and
costs of clinical trials, the timing and costs of other expenses;
market acceptance of our products; the ultimate impact of the
current Coronavirus pandemic, or any other health epidemic, on our
business, our clinical trials, our research programs, healthcare
systems or the global economy as a whole; our intellectual
property; our reliance on third party organizations; our
competitive position; our industry environment; our anticipated
financial and operating results, including anticipated sources of
revenues; our assumptions regarding the size of the available
market, benefits of our products, product pricing, timing of
product launches; management's expectation with respect to future
acquisitions; statements regarding our goals, intentions, plans and
expectations, including the introduction of new products and
markets; and our cash needs and financing plans. There are a number
of factors that could cause actual events to differ materially from
those indicated by such forward-looking statements. You should not
place reliance on these forward-looking statements, which include
words such as "could," "believe," "anticipate," "intend,"
"estimate," "expect," "may," "continue," "predict," "potential,"
"project" or similar terms, variations of such terms or the
negative of those terms. Although the Company believes that the
expectations reflected in the forward-looking statements are
reasonable, the Company cannot guarantee such outcomes. Hoth may
not realize its expectations, and its beliefs may not prove
correct. Actual results may differ materially from those indicated
by these forward-looking statements as a result of various
important factors, including, without limitation, market conditions
and the factors described in the section entitled "Risk Factors" in
Hoth's most recent Annual Report on Form 10-K and Hoth's other
filings made with the U. S. Securities and Exchange Commission. All
such statements speak only as of the date made. Consequently,
forward-looking statements should be regarded solely as Hoth's
current plans, estimates, and beliefs. Investors should not place
undue reliance on forward-looking statements. Hoth cannot guarantee
future results, events, levels of activity, performance or
achievements. Hoth does not undertake and specifically declines any
obligation to update, republish, or revise any forward-looking
statements to reflect new information, future events or
circumstances or to reflect the occurrences of unanticipated
events, except as may be required by applicable law.
Investor Contact:
LR Advisors LLC
Email: investorrelations@hoththerapeutics.com
www.hoththerapeutics.com
Phone: (678) 570-6791
View original content to download
multimedia:https://www.prnewswire.com/news-releases/hoth-therapeutics-announces-positive-preclinical-end-point-results-of-ht-alz-treatment-for-alzheimers-disease-301896478.html
SOURCE Hoth Therapeutics, Inc.